ストックスクリーナーアプリを入手
2.46
2.77%
-0.07
Seres Therapeutics Inc (MCRB) 最新ニュース
Seres Therapeutics stock at EUR 2.28, USD 25.2 million market value - ad-hoc-news.de
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 - GlobeNewswire Inc.
A liquid experimental treatment reduced two bacteria up to 1,000-fold in preclinical tests. - Stock Titan
Seres Therapeutics to Present Preclinical Data for - GlobeNewswire
Analysts see USD 17 target for Seres Therapeutics stock - AD HOC NEWS
Seres Therapeutics leaves S&P Global BMI Index. Seres Therapeutics stock gains 1.16 percent - AD HOC NEWS
Seres Therapeutics (Nasdaq:MCRB)Stock Analysis - Simply Wall Street
Seres Therapeutics, Inc.(NasdaqGS: MCRB) dropped from S&P Global BMI Index - marketscreener.com
Seres Therapeutics stock holds steady as investors await next catalysts - AD HOC NEWS
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new hires get options on 4,200 Seres shares - stocktitan.net
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences - Yahoo Finance
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - stocktitan.net
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Seres Therapeutics Inc. (MCRB) Peer Comparison – Compare with Others - Value Research
Seres Therapeutics Inc. (MCRB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Seres (MCRB) Earnings Report: The Available Earnings Metric Delivers a Beat; Post-Report: The Stock Ends Up 2.19%Profit Growth Outlook - vinanet.vn
MCRB|Seres Therapeutics Inc|Price:4.660|Chg%:+0.100 - TradingKey
Seres Therapeutics, Inc. SEC Filing (Aug 24, 2026) - Stock Titan
Seres Therapeutics reports positive SER-155 irEC study results - scanx.trade
Seres Therapeutics director Eric Shaff sells $1,196 in shares By Investing.com - Investing.com South Africa
Seres Therapeutics director Eric Shaff sells $1,196 in shares - Investing.com
Seres Therapeutics director Eric Shaff sells $1,196 in shares By Investing.com - Investing.com UK
Seres Therapeutics director Eric Shaff sells $1,196 in shares - Investing.com
Seres Therapeutics (NASDAQ: MCRB) COO sells 64 shares after 181 RSUs vest - Stock Titan
Seres Therapeutics (MCRB) director sale tied to RSU tax plan - Stock Titan
Seres Therapeutics, Inc. Revenue Breakdown – NASDAQ:MCRB - TradingView
Seres TherapeuticsMay Offer Up To $300 Million Of Securities - TradingView
Seres Therapeutics Files $300 Million Mixed Shelf - finance.yahoo.com
Seres Therapeutics Inc (MCRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Seres Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Seres Therapeutics exits more Cambridge real estate early - The Business Journals
Seres Therapeutics Inc earnings beat by $2.77, revenue topped estimates - Investing.com
Seres Therapeutics Q2 Operating Income USD -2 - Moomoo
Seres Therapeutics, Inc. 2Q 2026: Revenue $0.736M, Net income $4.581M, EPS $0.47— 10-Q Summary - TradingView
Seres Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Seres Therapeutics (MCRB) Q2 Revenue Surpasses Expectations Amid Clinical Progress - GuruFocus
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs - The Manila Times
Seres Therapeutics Q2 Net Income Reaches $4.6 Million - Quiver Quantitative
Seres Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Seres Therapeutics reports Q2 2026 net income of $4.6M, cash $15.6M, advances SER-155 clinical plans - TradingView
MCRB: Returned to profitability in Q2 2026, driven by VOWST sale gains and SER-155 trial success - TradingView
Q2 2026 financial results released as Seres Therapeutics advances business update - Traders Union
Seres Therapeutics Reports Second Quarter 2026 Financial - GlobeNewswire
Seres Therapeutics Reports Second Quarter 2026 Financial - globenewswire.com
Seres Therapeutics: Q2 Earnings Snapshot - Yahoo Finance
Seres Therapeutics Streamlines Cambridge Operations with Lease Changes - TipRanks
4.22%
大文字化:
|
ボリューム (24 時間):